JPMorgan analyst Jessica Fye upgraded United Therapeutics to Overweight from Neutral with a price target of $120, up from $116. The analyst says that after two reported quarters of minimal generic impact to Remodulin and recent management comments supportive of this trend despite two additional approvals, she is increasingly confident in Remodulin's "resilience" through 2020. The analyst expects 2020 will be a year characterized by upward estimate revisions for United's base business. The Street might be overly conservative in modeling Remodulin franchise the coming quarters, Fye tells investors in a research note.